England

Schweizer Damennationalmannschaft bezwingt Ungarn 3:2 in Wembley; Doutaz sichert entscheidenden Siegpunkt Team-WM: Schweiz bezwingt Ungarn mit 3:2 – Swiss Table Tennis Team-WM: Schweiz bezwingt Ungarn mit 3:2 Die Schweizer Damennationalmannschaft lieferte sich mit Ungarn in der Preliminary Round einen intensiven Schlagabtausch, in dem erst das fünfte Einzel über Sieg und Niederlage entscheiden sollte. Nachdem bisher immer Fanny Doutaz den Anfang gemacht hatte, bestritt nun Rachel Moret (WR 143) gegen Rebeka Nagy (WR 539) das Auftaktspiel. Moret geriet gleich zu Beginn in Rücklage und 3:7 in Rückstand, zwang aber anschliessend mit ihrer Aufholjagd noch im ersten Satz ihre Gegnerin zu einem Timeout. Moret blieb jedoch konstant und sicherte sich den ersten Satz mit 11:8. In der Folge übernahm Nagy allerdings zunehmend die Kontrolle über das Spiel. Dank konsequenter Chancenverwertung konnte sie jeweils ihren Vorstand über die Zeit bringen und entschied die nächsten drei Durchgänge mit 11:6, 11:5 und 11:7 für sich, wobei Moret im letzten Satz noch eine strenge gelbe Karte erhielt. ...

Yto Barrada unveils ‘Comme Saturne’ at Venice Biennale, France pavilion; devoré fabric central to installation Yto Barrada weaves histories of beauty and destruction at the Venice Biennale | Art Basel It’s weeks away from the opening of the Venice Biennale and most sites in the Giardini, the famous landscaped gardens to the eastern edge of the floating city, are still unfinished, abuzz with activity. ‘It’s hard to see anything because they’re planting trees, and the gardens are like a beehive,’ Yto Barrada tells me over the phone, while taking a pause from installing ‘Comme Saturne’, the project with which the Paris-born, Tangier-raised artist is representing France. ...

Mark Dawson Leiter Roche Pharma Forschung und Frühe Entwicklung (pRED) Basel; seit 2025 Roche | Prof. Dr. Mark Dawson Leiter Roche Pharma Forschung und Frühe Entwicklung (pRED) (Mitglied der erweiterten Konzernleitung seit 2026) 1993–1999Universität Melbourne, Bachelor of Medicine, Bachelor of Surgery (MBBS) 1999Universität Melbourne, Bachelor of Medical Science (BMedSci.) 2003–2007Fellowship of Royal Australasian College of Physicians (FRACP) 2003–2007Fellowship of Royal College of Pathologists of Australasia (FRCPA) 2007–2009Universität Cambridge, Promotion in Molekularbiologie (PhD) ...

Vivien and Emma attend English lessons at the International School, Torquay; awkward at first, became amazing experience. Tag 2 Torquay Day 2 Torquay This day was very special because it was our first full day here in Torquay. During the morning we attended the International School where we had English lessons. They were fun to attend. The teacher Loui is friendly and makes classes fun. That is why we liked both him and the classes. In the afternoon we visited the harbour where we did a task similar to a scavenger hunt. We were divided into groups of 3-4 people. The tasks were the same for everyone. The teachers wanted us to do such things as talking to unfamiliar people and finding interesting aspects about Torquay. We even had to ask strangers about their favorite ice-cream. At first we felt quite awkward but then it turned out to be an amazing experience. ...

Seleções brasileiras vencem Hungria e Tchéquia em Londres; avançam para a fase eliminatória Com vitória de virada do time masculino, seleções brasileiras vencem mais duas no Mundial por Equipes de Tênis de Mesa 2026 Com vitória de virada do time masculino, seleções brasileiras vencem mais duas no Mundial por Equipes de Tênis de Mesa 2026 Nesta quarta-feira (29) em Londres, time feminino venceu a Tchéquia e o masculino a Hungria, pela segunda rodada do torneio. Na quinta (30), equipes do Brasil poderão fechar na liderança da primeira fase em suas respectivas chaves e já avançar para a próxima etapa. Veja como foi. ...

面手凛 初出場の18歳、世界卓球選手権2026ロンドン大会（団体戦）; 55年ぶりの金メダルを目指す 卓球世界選手権、初出場の18歳・面手凛とは？ 世界卓球選手権2026ロンドン大会（団体戦）がいよいよ始まった。55年ぶりの優勝を目指す女子代表5人の精鋭チームには、高校を卒業したばかりの18歳、面手凛（めんで・りん）が名を連ねた。 日本女子卓球界の若手といえば、17歳の張本美和が先頭に立ち、今や世界ランキングで日本勢トップに君臨する選手へと成長している。その張本世代のナンバーツーとされるのが、全日本ジュニア選手権で2年連続準優勝を果たした1歳上の面手凛（めんで・りん）だ。英国の首都ロンドンで、初めてシニア世界選手権（2026年4月28日〜5月10日）の表舞台に立つ。 55年ぶりの優勝を目指す日本代表女子チーム5人は、世界ランキング最上位者、国内選考会優勝者、強化本部推薦をもとに選出された。その顔ぶれをみると、張本美和（世界ランキング5位／17歳）、早田ひな（同11位／25歳）、橋本帆乃香（同15位／27歳）、長﨑美柚（同16位／23歳）が名を連ね、4選手が世界ランキング20位以内の精鋭たち。そこに、2月の選考会で優勝候補を退けて代表の座を掴み取った18歳の面手が加わった。 世界ランキングは125位。子どもの頃から張本と同じ舞台で戦い、昨年インターハイを制した後、春に高校を卒業した。4月には初めてナショナルチームにも選出された面手とはどんな選手なのか？ ※世界ランキングは4月27日付 インターハイ優勝（2025年）、全日本ジュニアも2年連続準優勝の18歳・面手凛 面手凛は岡山県玉野市出身、2007年12月31日生まれの18歳。実業団出身の母の影響で3歳から卓球を始めた。 面手の心に火をつけたのは、小学4年のときに出場した全日本選手権（カブの部）だった。それまで全国規模で活躍することはなかったが、同大会で初の全国制覇を果たし、「卓球を本気で頑張ろうかなと思えた」（TBSのインタビューより）。それは同時に、世界の舞台に「本気で立ちたい」と思った経験にもなった。 山陽学園中学校に進み、最後の年には全国中学校体育大会で優勝し、高校最後のインターハイも制覇。各世代の大会を確実に抑えてキャリアの基盤を作りあげた。全日本選手権ジュニア女子では2年連続で決勝で張本と激突。2024年はストレート負けを喫し、翌年は1-3で負けたが、成長を感じる敗北だった。 日本代表の先輩たちとの試合でも対等に戦えるほどに腕を磨いている。 世界卓球の代表選考会が行われ2月。3ゲームマッチを5試合戦い、そのうち落としたゲームは長﨑と対戦した準決勝（3-1）の1ゲームのみ。優勝候補と目された長﨑をバックハンドとスピードで翻弄し、勝利をつかんだ。 2025年から所属する「日本生命レッドエルフ」の一員として戦ったシーズンプレーオフ（3月）では、最終的にチームは敗れたものの、重要な場面でオリンピック2大会出場の平野美宇を相手に勝利をあげた。 伸び盛りの18歳は世界トップの戦いで何を得るのか？ 100周年を迎える今年の世界卓球は団体戦が行われ、世界一のチームを決める。東京で開かれた2014年大会以降、日本女子チームは5大会連続で中華人民共和国代表チームに敗れ準優勝。今年のメンバーは「金メダルしか見ていない」と口をそろえ、55年ぶりの金メダルを目指す。 その中で面手は定評のあるバックハンドを武器にしながら、フォアハンドも強化中。スピードのある高速ラリーで相手に挑み、ロンドンの観客を楽しませることになるだろう。 世界卓球に向けて思うことは、「海外のトップ選手と試合をしてもっと強くなりたい」（KBC瀬戸内放送のインタビューより）ということ。 オリンピック出場も目指す18歳にとって、世界のトップ選手と戦う貴重な機会になるだけでなく、強豪・日本代表の新戦力として、番狂せを起こす可能性も秘めている。

Rolls-Royce Holdings plc AGM Statement and Trading Update global; Guidance for 2026 unchanged despite Middle East conflict Rolls-Royce Holdings plc AGM Statement and Trading Update | Rolls-Royce Thursday 30 April 2026 07:00 AM Trading update to 31 March 2026 We have had a strong start to the year across all three divisions. We continue to deliver on our transformation and are proactively mitigating the impact associated with the conflict in the Middle East. As a result, our guidance for 2026 of £4.0bn-£4.2bn of underlying operating profit and £3.6bn-£3.8bn of free cash flow remains unchanged. Year-on-year growth in profit and cash flow across the Group continues to be largely driven by our actions and strategic initiatives. Rolls-Royce has a diversified and resilient portfolio of businesses. Widebody demand remains strong, and we have a young fleet which is growing faster than the market. In addition, business aviation, Defence, and Power Systems are all highly resilient businesses with growth outlooks remaining highly attractive. Civil Aerospace had a strong start to the year driven by large engine and business aviation aftermarket, with business aviation flying hours ahead of budget. Large EFH (engine flying hours) grew by 5% to 115% of 2019 levels in the three months to 31 March. For the full year 2026, we continue to expect large EFH at 115%-120% of 2019 levels: - There has already been a significant recovery in EFH of Middle Eastern airlines, with EFH of Trent XWB engines fully recovered to pre-conflict levels. - EFH growth in other regions remains strong, benefiting from the reallocation of capacity and our improved operational performance, including fewer AOG (aircraft on ground). - The vast majority of economically driven airline capacity reductions announced year-to-date have been narrowbody. - We do not expect a change in the retirement profile of the Trent 700, which remains the most fuel-efficient engine on the Airbus A330ceo platform, with the majority of the fleet contracted up to the 2030s. Trent 700 EFH in the three months to 31 March were higher year-on-year. We continue to see good operational momentum: - Growth in large engine OE deliveries in the first quarter was 18% and our guidance for the full year remains unchanged. - Growth in large engine shop visits in the first quarter was 12%. Given our predominantly total service business model, which allows us to better plan for shop visits, we do not expect a change in our large engine shop visit profile in 2026 and 2027 as a result of the Middle East conflict. - The number of AOG fell to a single-digit level at the end of April, a best-in-class level for the industry, and we continue to target zero AOG by the second half of the year. Demand for new widebody aircraft remains firm. We announced significant orders in the period, including 40 Trent XWB-97 engines for Atlas Worldwide that will power 20 A350F freighter aircraft, alongside 30 Trent XWB-84 EP and 32 Trent 7000 engines for Delta Air Lines. Orders for Trent 1000 XE engines on eight Boeing 787 aircraft in April provide clear evidence that our sustained investment in durability improvements has repositioned the Trent 1000 XE as a competitive, order‑winning engine, while continuing to benefit from our good aftermarket services offering. Our time on wing programme is progressing to plan. Having certified the second phase of HPT blade improvements for the Trent 1000 and Trent 7000 at the end of last year, we have begun installing the new blade in OE deliveries and during shop visits. We have now upgraded more than a third of the Trent 1000 TEN operational fleet with improved HPT blades, bringing them to the new enhanced Trent 1000 XE standard of durability. We are also continuing to grow our MRO capacity. In January, Turkish Technic broke ground on a state-of-the-art independent maintenance centre in Istanbul, targeted to be operational by the end of 2027, supporting up to 200 shop visits annually. In Defence, a strong start to the year was driven by improved aftermarket performance alongside more than a 20% year-on-year increase in OE deliveries. Demand remains high for both our mature and new programmes. Our unique positioning in next-generation autonomous aircraft propulsion was demonstrated by the first flight of the U.S. Navy’s MQ-25 autonomous refuelling aircraft in April, powered by our AE 3007 engine. In March, Rolls-Royce, as the lead partner in the EUROJET consortium, received an order to provide EJ200 engines that will power Türkiye’s new fleet of 20 Eurofighter Typhoons. In April, our MT30 marine gas turbine was selected to power up to 11 of the Australian Navy’s new fleet of general-purpose frigates, helping to enhance undersea warfare and air defence capabilities. On future programmes, engine testing for the U.S. Army’s MV-75 Cheyenne II is progressing well with endurance and altitude testing on track for later this year, as we keep pace with the accelerated production timeline. In March, we collaborated closely with Boeing on the next stages of their critical design review, for the U.S. Air Force’s B-52, which will be re-engined with our F-130 engine. Power Systems also had a strong start to the year driven by power generation, led by data centres, and governmental. Demand remains high, with power generation order intake across gas and diesel engines in the first quarter around 50% higher than last year, and revenue growth was also strong. March was a record month for orders. As a result, Power Systems’ order backlog stood at £7.3bn at 31 March. In January, we announced that we will be supplying 350 upgraded mtu Series 199 engines on new Boxer armoured wheeled vehicles for the German Armed Forces and other international customers. In March, we announced an order for around 200 compact mtu PowerPacks for the Bundeswehr’s Puma armoured personnel carrier and signed a memorandum of understanding with the largest defence technology group in Poland, Polska Grupa Zbrojeniowa S.A. (PGZ), to provide services to mtu engines used by the Polish armed forces. Also in March, Power Systems signed a contract with Voltaria Helios Energy Storage to build a large-scale battery energy storage facility in Scotland. In April, Rolls-Royce SMR finalised and signed the contract with GBE-N to supply the UK with three small modular reactors (SMR) at Anglesey, Wales. Commercial terms were also signed with the ČEZ Group, enabling work to progress at the Temelin site for the first of up to six SMRs in the Czech Republic. Both contracts have now entered the execution phase and will generate revenues and profits this year. Rolls-Royce SMR is the only company with multiple contractual commitments to deliver SMR units in Europe and is well placed to become a market leader globally. Our balance sheet remains strong, and the credit ratings agencies continue to recognise the progress that we are making, with both Moody’s and Fitch upgrading our credit rating to A3 and A-, respectively, both with a stable outlook. In February, we repaid a €750m bond from free cash flow. We are making good progress with the £2.5bn 2026 tranche of our £7bn-£9bn share buyback across 2026-2028, having completed more than £750m to date. Our 2026 Half Year results will be announced on 30 July 2026.

Bank of England MPC belässt Bank Rate bei 3,75% in London; Zinserhöhung nicht ausgeschlossen Quelle: Bank of England, NORD/LB Research Das MPC der Bank of England hat heute beschlossen die als Leitzins bekannte Bank Rate bei 3,75% zu be- lassen – vorerst! Aufgrund der geopolitischen Lage haben die Notenbanker zunächst kein Interesse die Zinsen zu senken. Tatsächlich könnte der jüngste Senkungszyklus sogar beendet sein, so legt es jeden- falls das soeben veröffentlichte Sitzungsprotokoll nahe. Es herrscht allgemein viel Unsicherheit in der Weltwirtschaft, welche sich schlecht in klare Prognosen einbetten lässt. Die Bank of England wird künftig also zurückhaltend agieren wollen wird. Mit jedem Tag mehr, den die Straße von Hormus blockiert ist und folglich die Energiepreiskomponenten der nationalen Vebraucherpreisindizes nach oben treibt, sinkt die Wahrscheinlichkeit von zeitnahen Zinssenkungen. Dies betrifft auch die britische Volkswirtschaft, welche jüngst ebenfalls eine vergleichs- weise hohe Inflationsrate von 0,7% im Vergleich zum Vormonat veröffentlichte. Dies ist der zweithöchste Wert seit fast drei Jahren, nur übertroffen von dem Kurzfristschock nach dem von US-Präsident Trump ausgerufenen „Liberation Day“. Die Mitglieder des MPC haben demnach mit acht Stimmen für einen Ver- bleib des derzeitigen Leitzinsniveaus auf 3,75% gestimmt. Huw Pill hätte die Bank Rate sogar um 25 Ba- sispunkte angehoben. Dies sollte zwar nicht überbewertet werden, da Pill eher als leicht restriktiver Geld- politiker in Erscheinung getreten ist. In Summe hat das Gremium aber klar gemacht, dass die Zeit gegen eine baldige Lockerungspolitik spielt und schließt eine Anhebung bei der nächsten Sitzung nicht aus. Die Notenbanker aus London treibt die Sorge vor Zweitrundeneffekten um. Einerseits steigen die Preise an den Ladentheken und Zapfsäulen und natürlich auch bei diversen Vorprodukten von Industrie und Dienstleistern. Andererseits ist die Arbeitslosenquote jüngst überraschend gesunken, auch wenn sich die Arbeitsmarktindikatoren in Summe etwas uneinheitlich zeigten. Übersetzt heißt dieser Mix aus einer dy- namischen Inflationsrate und eines möglicherweise erstarkenden Arbeitsmarktes, dass das Schreckge- spenst der Lohn-Preis-Spirale wieder spukt. Für viele Notenbanker ein regelrechtes Horroszenario, die Briten waren hier im westeuropäischen Vergleich allerdings auch leidgeplagt. Die Historie gemahnt dem- nach zur Vorsicht, auch wenn die mutmaßliche Preisentwicklung eher einem Worst-Case Szenario ent- sprechen dürfte. Die Devise ist sodann lieber zeitig entsprechende Maßnahmen zu ergreifen und den Zins anzuheben, als die Güterpreise aus dem Ruder laufen zu lassen – bei der nächsten Zinssitzung ist alles möglich, in sieben Wochen kann allerdings auch viel passieren. ...

Nexans acquires Republic Wire, Inc; €680m EV, earn-out up to €43m White & Case advises Nexans on €680 million acquisition of Republic Wire | White & Case LLP White & Case advises Nexans on €680 million acquisition of Republic Wire Global law firm White & Case LLP has advised Nexans on its acquisition of Republic Wire, Inc. The transaction represents a total enterprise value of €680 million, with a further earn-out of up to €43 million potentially payable in 2028, based on performance through year-end 2027. ...

Polly Cooper, Clinical Development Function Head, UK; rejoined Novartis amid AI-driven transformation Full Circle: A Story of Growth, Purpose and Coming Home to Novartis | Novartis People and Culture Full Circle: A Story of Growth, Purpose and Coming Home to Novartis Polly Cooper, Clinical Development Function Head, UK Apr 28, 2026 I had always dreamed of working with racehorses; however, my father encouraged me to stay at school and finish my A levels. So, I followed the sensible path: taking the exams, moving to Covent Garden, London, and starting work as an estate agent. I really loved that job yet a part of me never let go of the dream of becoming a jockey. So, I took a chance and started a job in racing based in Ascot, however it was not the career for me and I returned home six months later unsure of what would come next. As fate would have it, my uncle, a medic, was visiting from Australia. He had such fascinating stories of his work as a Diplomat - being in Tiananmen Square during the revolution and then in Red Square in China for the riots. He inspired me to open my mind to new possibilities. He was also the one who spotted an ad in the newspaper for a Lab Technician role at CibaGeigy and encouraged me to apply. I had no formal scientific qualifications, although I’d always loved science thanks to my unforgettable teachers who had brought it to life in school. I was convinced I wouldn’t be hired. I must have displayed something in those interviews, because to my amazement, a week before my 21st birthday I stepped into the labs as part of the formulation development team for over-the-counter medicines. It was exciting, energizing - and it felt like the start of a real career. As time went on, I noticed my colleagues had qualifications I didn’t yet hold. If I wanted to grow, I needed to invest in myself. Supported by the company, I spent one day a week studying for my Higher National Certificate in Pharmaceutical Science, and then for my Pharmacology degree. When CibaGeigy merged with Sandoz in 1996, I found myself part of the newly created Novartis - a turning point that opened doors into Clinical Pharmacology and later into a series of roles that shaped the career I’m so grateful for today. Support from colleagues and leaders who believed in me made everything possible, even my MBA sponsorship. I saw a company transformed - more focused, more technologically advanced, integrating AI into daily decision making and strengthening its identity as a pure-play innovative medicines company anchored in five core therapeutic areas. It felt like stepping back into the future. Polly , Clinical Development Function Head, UK Redundancy, Reinvention… and an Unexpected Homecoming More than a decade later, when Novartis closed the UK site in Horsham, I had the chance to relocate to Basel. But with a newborn at home, the timing just wasn’t right. I left and transitioned into a leadership role in Pharmaceutical Product Development (PPD) - fascinating work, fast-paced and deeply engaging. Yet I found myself missing something: the full picture of drug development that Novartis offered. Contract Research Organizations (CROs) taught me depth and speed. Whereas Novartis had always offered breadth, integration and the sense that all parts of the puzzle connected under one roof. In 2025 when the company I was working for restructured, I found myself looking ahead and asking myself what I truly wanted next. I knew I didn’t want ‘more of the same’ - I wanted growth, purpose, stretch. When I saw Novartis was hiring again in the UK, I applied. I didn’t get the first role - and that was humbling. It reminded me that Novartis truly attracts exceptional talent, and you need resilience and belief in yourself to put yourself amongst those people. Re- energised, I re-entered the process and was eventually rehired into my current role - and it genuinely felt like coming home. There were the familiar faces, some of the same projects, and the same culture of humanity that makes Novartis special. Yet I also saw a company transformed - more focused, more technologically advanced, integrating AI into daily decision making and strengthening its identity as a pure-play innovative medicines company anchored in five core therapeutic areas. It felt like stepping back into the future. What would I say to anyone thinking of returning to or joining Novartis? This place is extraordinary - not because of buildings or branding, it’s because it invests in people. When I left, I gained invaluable experience across other organizations. But coming back allowed me to channel everything I had learned into helping others with opportunities to grow. Novartis supported my education and development; now I get to pay it forward. If you’re considering returning as an alum - or joining for the first time - ask yourself: What energy will you bring? What curiosity drives you? How deeply do you care about people and patients? Where do you want your talent to make an impact? Because if you bring ability, agility and aspiration, this is a place where you can thrive - and help reimagine medicine for the world. Learn more about opportunities across R&D here: Career Search | Novartis ...